Tofersen

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

Conditions

ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

Trial Timeline

Mar 8, 2017 → Aug 12, 2024

NCT ID

NCT03070119

About Tofersen

Tofersen is a phase 3 stage product being developed by Biogen for ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation. The current trial status is completed. This product is registered under clinical trial identifier NCT03070119. Target conditions include ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04972487	Pre-clinical	Completed	—	—	Superoxide Dismutase 1-Amyotropic Lateral Sclerosis
NCT07259980	Pre-clinical	Recruiting	Mar 31, 2026	Dec 30, 2033	Amyotrophic Lateral Sclerosis
NCT07294144	Phase 2	Recruiting	Dec 29, 2025	May 1, 2028	ALS (Amyotrophic Lateral Sclerosis)
NCT07223723	Approved	Recruiting	Dec 11, 2025	Dec 16, 2027	Amyotrophic Lateral Sclerosis
NCT03070119	Phase 3	Completed	Mar 8, 2017	Aug 12, 2024	ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

Competing Products

7 competing products in ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

See all competitors

Product	Company	Stage	Hype Score
E3810 + E3810 + Teprenone	Eisai	Phase 2/3	65
Rabeprazole + Rabeprazole	Eisai	Phase 2/3	65
RotaTeq (V260) + IPV	Merck	Phase 3	77
Ceftolozane-Tazobactam + Meropenem	Merck	Phase 3	77
Hib-CRM197 + Hib-TT	Novartis	Phase 3	77
13-valent Pneumococcal conjugate vaccine	Pfizer	Approved	84
Elinzanetant (BAY3427080) + Placebo	Bayer	Phase 3	74

Other Products from Biogen

Interferon-beta-1a + methylprednisoloneApproved

Dimethyl fumarateApproved

[18F]Florbetapir PET imagingApproved

dimethyl fumarateApproved

ibritumomab tiuxetan (Zevalin®)Approved